Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA4 | P22748 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.33 |
| ▸ | CTH | P32929 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | EPOR | P19235 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740911 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ALMNACA2 | |
| SCHEMBL3802664 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ALMNACA2 | |
| SCHEMBL14740842 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ALMNACA2 | |
| SCHEMBL12476057 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ALMNACA2 | |
| SCHEMBL14740963 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ALMNACA2 | |
| SCHEMBL1164116 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ALMNACA2 | |
| SCHEMBL25385243 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ALMNACA2 | |
| SCHEMBL16756668 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ALMNACA2 | |
| Hydrochloric Acid SCHEMBL23441155 | 0.98 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2ALMNACA2 | |
| Hydrochloric Acid SCHEMBL23111798 | 0.98 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2ALMNACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2023172889-A1 | USE OF CHEMICAL EPIGENETIC MODIFIERS TO MODULATE GENE EXPRESSION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-4221756-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023080652-A1 | ANDROGEN RECEPTOR DEGRADERS FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AND USE THEREOF | AUTOTAC INC. (KR) | 2023-05-11 | — | — | WO | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| WO-2021022076-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013033268-A2 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | SMN1; SMN2 4253/4885MEN1 3820/4885KMT2A 408/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | SMN1; SMN2 2621/4885MEN1 3254/4885KMT2A 1342/4885 |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | SMN1; SMN2 1457/4885MEN1 153/4885KMT2A 1097/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | SMN1; SMN2 2621/4885MEN1 3254/4885KMT2A 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.